StockData
ADC Therapeutics SA logo

ADC Therapeutics SA (ADCT) stock

ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$1.34−0.07 (-4.96%)

Close on Nov 13, 2026Market cap $171.08MP/E –Yield –

Earnings

ADC Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 9, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$21.00M
+32.9% on a year earlier
Adjusted EPS, Q3 FY2026
–
-$0.19 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of ADC Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Mar 9, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 9, 2026before the open$21.00M+32.9%––Release
Q2 FY2026ended Jun 30, 2026Aug 13, 2026before the open$19.25M+2.2%-$0.11-$0.11Release
Q1 FY2026ended Mar 31, 2026May 4, 2026before the open$20.85M-9.5%-$0.21-$0.13Release
Q4 FY2025ended Dec 31, 2025Mar 10, 2026before the open$23.06M+36.4%-$0.04-$0.09Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025before the open$15.80M–-$0.30-$0.19Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025before the open$18.84M+8.2%-$0.50-$0.25Release
Q1 FY2025ended Mar 31, 2025May 14, 2025before the open$23.03M+27.6%-$0.36-$0.22Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025before the open$16.91M+0.7%-$0.29-$0.25Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open––––Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024before the open$17.41M–-$0.38-$0.25Release
Q1 FY2024ended Mar 31, 2024May 6, 2024before the open$18.05M–-$0.56-$0.38Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

ADC Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When ADC Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases ADC Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates
    Results
  2. ADC Therapeutics Announces Abstracts at the 68th
    Results
  3. Corporate Webcast ASH Abstract Update November 4, 2026
    Results
  4. ADC Therapeutics Announces Comprehensive Strategic
    Results
  5. Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
    Results
  6. LOTIS - 5: Forest Plot of Progression Free Survival by IRC In favor of ZYNLONTA+R In favor of R - GemOx ITT population, N=420; Data cut off: February 16, 2026. Corporate Presentation | 44
    Results
  7. Therapeutics Announces Strategic Reorganization to Support ZYNLONTA ® Growth Opportunities and Regulatory Priorities
    Update
  8. Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA ® in Combination with Rituximab in Relapsed or Refractory
    Update
  9. LOTIS - 5 Topline Results Presentation JUNE 3, 2026
    Update
  10. ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
    Results
  11. ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
    Results
  12. 8-K exhibit EX-99.1
    Update
  13. ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
    Results
  14. ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
    Results
  15. ADC Therapeutics Announces $60 Million Private
    Results

See a number that looks wrong?